SLC25A19: A Drug Target and Potential Biomarker for Mitochondrial Thiamine Pyrophosphate Carrier

Target Name: SLC25A19

NCBI ID: G60386

SLC25A19

SLC25A19: A Drug Target and Potential Biomarker for Mitochondrial Thiamine Pyrophosphate Carrier

Thiamine pyrophosphate (TPP) is a crucial coenzyme for the citric acid cycle (CAC), a central metabolic pathway that generates energy in the form of ATP. Mitochondria produce most of the ATP in the cell, and TPP is a key carrier for ensuring that adequate levels of ATP are available for the cell's various functions. The mitochondrial thiamine pyrophosphate carrier (SLC25A19) is a protein that plays a significant role in regulating TPP levels and is the target of several ongoing clinical trials.

SLC25A19 functions as a transporter for the protein TPP, which is synthesized in the cytoplasm and then transported to the mitochondria where it is used for the production of ATP. It is a member of the SLC transporter family, which includes several related proteins that are involved in the transport of various types of ions and molecules across cell membranes. SLC25A19 is unique, however, in its role as a TPP carrier and its central role in the regulation of ATP production.

SLC25A19 has been identified as a potential drug target for several reasons. Firstly, SLC25A19 is a protein that is expressed in high levels in various tissues, including the brain, heart, and muscle. This makes it an attractive target for drugs that are designed to modulate TPP levels or improve ATP production. Secondly, SLC25A19 has been shown to play a role in several diseases, including Alzheimer's disease, Parkinson's disease, and cardiovascular disease. The underlying mechanisms of these diseases are often related to the dysfunction of TPP and ATP production, which suggests that SLC25A19 may be a useful biomarker or drug target.

SLC25A19-based therapeutics have the potential to treat a range of disorders associated with TPP and ATP production. For example, SLC25A19 has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. These conditions are characterized by the progressive loss of brain cells and the development of characteristic symptoms that are thought to be caused by the dysfunction of TPP and ATP production. SLC25A19-based therapeutics may be able to treat these conditions by modulating TPP levels or improving ATP production.

Another promising application of SLC25A19 is its potential as a biomarker for the diagnosis and monitoring of TPP-related disorders. The dysfunction of TPP and ATP production is often detected by measuring the levels of SLC25A19 in various tissues, such as brain and muscle. By monitoring the levels of SLC25A19, researchers may be able to determine the severity of TPP-related disorders and to identify potential therapeutic targets.

In conclusion, SLC25A19 is a protein that plays a critical role in regulating TPP and ATP production in the mitochondria. Its potential as a drug target and biomarker makes it an attractive target for researchers who are interested in the development of therapies for TPP-related disorders. Further studies are needed to fully understand the role of SLC25A19 in these conditions and to determine its potential as a therapeutic agent.

Protein Name: Solute Carrier Family 25 Member 19

Functions: Mitochondrial transporter mediating uptake of thiamine diphosphate into mitochondria. It is not clear if the antiporter activity is affected by the membrane potential or by the proton electrochemical gradient

The "SLC25A19 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A19 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets